
Minerva Neurosciences NERV
$ 6.15
-1.6%
Quarterly report 2026-Q1
added 05-05-2026
Minerva Neurosciences P/CF Ratio 2011-2026 | NERV
Annual P/CF Ratio Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.57 | -0.697 | -3.2 | -0.403 | -0.174 | -3.95 | -7.23 | -5.83 | 78 | -12.7 | -5.02 | -1.55 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 78 | -12.7 | 2.72 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Esperion Therapeutics
ESPR
|
-42.9 | $ 3.13 | 0.55 % | $ 651 M | ||
|
Exelixis
EXEL
|
13.2 | $ 48.2 | 8.51 % | $ 13.1 B | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Fortress Biotech
FBIO
|
-1.18 | $ 2.53 | 2.85 % | $ 70.6 M | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Galapagos NV
GLPG
|
-8.78 | $ 28.81 | 1.48 % | $ 2.69 B | ||
|
Athira Pharma
ATHA
|
-0.0166 | - | - | $ 269 M | ||
|
Genmab A/S
GMAB
|
4.08 | $ 27.95 | 1.5 % | $ 17.2 B | ||
|
Genprex
GNPX
|
-0.108 | $ 0.91 | 2.24 % | $ 849 K | ||
|
Grifols, S.A.
GRFS
|
14.1 | $ 8.4 | 1.63 % | $ 6.83 B | ||
|
InflaRx N.V.
IFRX
|
-3.72 | $ 2.51 | 27.16 % | $ 152 M | ||
|
Ionis Pharmaceuticals
IONS
|
-48.1 | $ 77.0 | 2.33 % | $ 12.3 B | ||
|
BioNTech SE
BNTX
|
70.7 | $ 94.64 | -0.9 % | $ 27.2 B | ||
|
Kamada Ltd.
KMDA
|
-30.7 | $ 8.29 | 0.91 % | $ 260 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-0.982 | - | - | $ 231 M | ||
|
Kymera Therapeutics
KYMR
|
-34.1 | $ 85.79 | 3.72 % | $ 7.25 B | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.82 | $ 13.58 | 0.97 % | $ 1.8 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
22.9 | $ 231.58 | -0.31 % | $ 4.24 B | ||
|
INmune Bio
INMB
|
-1.25 | $ 1.54 | - | $ 38.1 M | ||
|
Liquidia Corporation
LQDA
|
-82.6 | $ 41.64 | 3.75 % | $ 3.58 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
20.2 | $ 22.58 | 1.03 % | $ 3.74 B | ||
|
Mirum Pharmaceuticals
MIRM
|
97.6 | $ 107.36 | 1.46 % | $ 5.39 B | ||
|
MannKind Corporation
MNKD
|
54.2 | $ 3.61 | 26.17 % | $ 1.1 B | ||
|
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-0.537 | $ 3.46 | -1.14 % | $ 5.7 M | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-1.17 | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
-0.0645 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-0.159 | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-5 | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
-0.976 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-0.632 | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-612 | $ 24.0 | 2.46 % | $ 3.05 B | ||
|
Nanobiotix S.A.
NBTX
|
-8.77 K | $ 41.6 | 19.64 % | $ 286 B | ||
|
Allena Pharmaceuticals
ALNA
|
-2.48 | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-0.0776 | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-0.236 | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-6.14 | - | - | $ 2.17 B |